Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 10/20 | 0.46 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.38 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.36 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.36 |
| ▸ | KMO | O15229 | 1/20 | 0.36 |
| ▸ | CDC42 | P60953 | 1/20 | 0.35 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.35 |
| ▸ | PKN2 | Q16513 | 1/20 | 0.35 |
| ▸ | JAK2 | O60674 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4295262 | 0.94 | CHEK1 (0.54) | CHEK1ROCK2CDC42ROCK1PKN2 | |
| SCHEMBL4295269 | 0.83 | CHEK1 (0.61) | CHEK1ROCK2TRPV1KDM4ENPSR1 | |
| SCHEMBL4300434 | 0.82 | CHEK1 (0.42) | CHEK1ROCK2 | |
| SCHEMBL4296686 | 0.77 | CHEK1 (0.73) | CHEK1KDM4E | |
| SCHEMBL4292052 | 0.77 | CHEK1 (0.65) | CHEK1KMOKDM4E | |
| SCHEMBL4287238 | 0.77 | CHEK1 (0.48) | CHEK1JAK2KDM4E | |
| SCHEMBL30037800 | 0.75 | ROCK2 (0.50) | ROCK2CDC42ROCK1PKN2 | |
| SCHEMBL5025815 | 0.74 | KDM4E (0.51) | CHEK1ROCK2KDM4E | |
| SCHEMBL4296227 | 0.74 | CHEK1 (0.54) | CHEK1KDM4E | |
| SCHEMBL4287142 | 0.73 | CHEK1 (0.44) | CHEK1KDM4ENPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090258852-A1 | Inhibitors of Checkpoint Kinases | MERCK SHARP & DOHME CORP. | 2009-10-15 | — | — | US | claimed |
| US-20090258852-A1 | Inhibitors of Checkpoint Kinases | MERCK SHARP & DOHME CORP. | 2009-10-15 | — | — | US | disclosed |
| US-20090258852-A1 | Inhibitors of Checkpoint Kinases | MERCK SHARP & DOHME CORP. | 2009-10-15 | — | — | US | disclosed |
| US-20090258852-A1 | Inhibitors of Checkpoint Kinases | MERCK SHARP & DOHME CORP. | 2009-10-15 | — | — | US | disclosed |
| WO-2007008502-A2 | INHIBITORS OF CHECKPOINT KINASES | MERCK & CO., INC. (US) | 2007-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090258852-A1 | Inhibitors of Checkpoint Kinases | CHEK1, CHEK2, CDKN1A | CHEK1 1/4885ROCK2 1117/4885TRPV1 4178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.